Shop Now Contact

Anti-Human DR5 (Drozitumab Biosimilar)

Cat # Size Price Quantity
5020011 mg$250
5020025 mg$750
50200320 mg$2000

  Bulk/Custom

Product Details

CloneDrozitumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human DR5 (Drozitumab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman DR5
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsTNFRSF10B
RRIDAB_3739296
Target NameCD262, DR5, TRAIL-R2, KILLER, TRICK2, Ly98, TNFRSF10B
Antibody TypeRecombinant
Research AreasCancer Marker, Monocytes, Neutrophils, B cells
See All FormatsClone Drozitumab

Background Information

Drozitumab, also known as PRO95780, is a fully human monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, designed to target death receptor 5 (DR5), also known as tumor necrosis factor receptor superfamily member 10B (TNFRSF10B). Structurally, Drozitumab consists of two identical heavy chains and two identical light chains linked by disulfide bonds, forming a Y-shaped configuration typical of immunoglobulins with a molecular weight of approximately 150 kilodaltons (kDa). It is produced using mammalian recombinant expression systems to ensure proper protein folding, assembly, and glycosylation. The molecule’s heavy and light chains contain variable domains that form the antigen-binding sites, each consisting of complementarity-determining regions (CDRs) responsible for recognizing the DR5 epitope.

Drozitumab binds specifically and with high affinity to DR5, a cell-surface receptor that functions as part of the extrinsic apoptosis signaling pathway. DR5 is one of the receptors that recognize tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). By mimicking the binding of endogenous TRAIL, Drozitumab acts as an agonistic antibody, promoting receptor trimerization, a process essential for activating downstream apoptotic signaling cascades. Upon receptor clustering, DR5 recruits adaptor proteins such as FADD (Fas-associated death domain) and initiates the assembly of the death-inducing signaling complex (DISC). This complex activates initiator caspases (particularly caspase-8), which in turn cleave and activate effector caspases (e.g., caspase-3) that execute apoptotic cell death.

The Fc region of Drozitumab provides molecular stability and may facilitate interactions with Fc gamma receptors (FcγRs), allowing immune-mediated effects such as crosslinking that enhance receptor clustering in vitro. Its structural design exemplifies the use of human IgG1 frameworks to combine precise antigen targeting, structural durability, and effective signal initiation. Overall, Drozitumab serves as a well-defined model of an agonistic monoclonal antibody engineered for selective engagement of the TRAIL-DR5 apoptotic pathway in molecular and cell death signaling research.

Data Sheets

Anti-Human DR5 (Drozitumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.